Fig. 5From: Therapy response testing of breast cancer in a 3D high-throughput perfused microfluidic platformOutlook: Work flow for Patient derived xenograft (PDX) vs cancer-on-a-chip drug screening. Compared to PDX drug screening, the compact OrganoPlate® platform is expected to reduce assay time and space, and increase the throughput of screened compounds, leading to improvements in cancer treatment planning and personalized medicine for individual patientsBack to article page